尿毒症性瘙痒的治疗:系统综述
该系统综述检索截至2017年3月6日的随机对照试验,纳入44项RCT、39种治疗,对象为晚期CKD(≥3期)或透析成人患者。加巴喷丁证据最多,其余治疗因试验有限无法评效,多数研究偏倚风险高。
要点
- 加巴喷丁是证据最多的尿毒症性瘙痒治疗。
- 39种治疗中多数因试验太少无法评价疗效。
- 现有证据整体偏弱,亟需大型严谨多臂RCT。
核心结论
- 除加巴喷丁外,当前尿毒症性瘙痒治疗的证据较弱。
研究设计与样本
- 系统综述,检索PubMed、CINAHL、Embase、International Pharmaceutical Abstracts、Scopus、Cochrane Library和ClinicalTrials.gov至2017年3月6日。
- 纳入44项RCT,受试者为晚期CKD(≥3期)或接受任何形式透析的成人患者。
- 由2名评价者独立提取数据,采用Cochrane协作网偏倚风险工具评估。
主要发现
- 44项RCT共评估39种不同治疗,包括加巴喷丁、普瑞巴林、肥大细胞稳定剂、光疗、血液透析调整及多种全身和局部治疗。
- 加巴喷丁的有效性证据体量最大。
- 其他治疗因试验数量有限,无法评价其疗效。
- 多数研究偏倚风险高。
关键数值与推荐
- 结局指标为视觉模拟、语言评分或数字评分量表上瘙痒强度的定量变化。
临床怎么用
- 临床可优先考虑加巴喷丁治疗尿毒症性瘙痒,但需注意多数研究偏倚风险高。
- 其他治疗因证据不足,选择时应谨慎并个体化。
局限性
- 设计、治疗和结局指标异质性大,难以比较且无法进行荟萃分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Uremic pruritus is a common and burdensome symptom afflicting patients with advanced chronic kidney disease (CKD) and has been declared a priority for CKD research by patients. The optimal treatments for uremic pruritus are not well defined. STUDY DESIGN: Systematic review. SETTING & POPULATION: Adult patients with advanced CKD (stage ≥ 3) or receiving any form of dialysis. SELECTION CRITERIA FOR STUDIES: PubMed, CINAHL, Embase, International Pharmaceutical Abstracts, Scopus, Cochrane Library, and ClinicalTrials.gov from their inception to March 6, 2017, were systematically searched for randomized controlled trials (RCTs) of uremic pruritus treatments in patients with advanced CKD (stage ≥ 3) or receiving any form of dialysis. 2 reviewers extracted data independently. Risk of bias was assessed using the Cochrane Collaboration risk-of-bias tool. INTERVENTION: Any intervention for the treatment of uremic pruritus was included. OUTCOMES: A quantitative change in pruritus intensity on a visual analogue, verbal rating, or numerical rating scale. RESULTS: 44 RCTs examining 39 different treatments were included in the review. These treatments included gabapentin, pregabalin, mast cell stabilizers, phototherapy, hemodialysis modifications, and multiple other systemic and topical treatments. The largest body of evidence was found for the effectiveness of gabapentin. Due to the limited number of trials for the other treatments included, we are unable to comment on their efficacy. Risk of bias in most studies was high. LIMITATIONS: Heterogeneity in design, treatments, and outcome measures rendered comparisons difficult and precluded meta-analysis. CONCLUSIONS: Despite the acknowledged importance of uremic pruritus to patients, with the exception of gabapentin, the current evidence for treatments is weak. Large, simple, rigorous, multiarm RCTs of promising therapies are urgently needed.
引用
- Simonsen E, Komenda P, Lerner B, et al. Treatment of Uremic Pruritus: A Systematic Review. Am J Kidney Dis. 2017. PMID: 28720208. doi:10.1053/j.ajkd.2017.05.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。